Counterpoint: Should Epidermal Growth Factor Receptor Mutations Be Routinely Tested for in Patients With Lung Cancer? NoNo Test for EGFR Mutations? No

David C. L. Lam, MBBS (HK), PhD (HK), FCCP

Author and Funding Information

From the Department of Medicine, University of Hong Kong.

Correspondence to: David C. L. Lam, MBBS (HK), PhD (HK), FCCP, Department of Medicine, University of Hong Kong, Queen Mary Hospital, 102 Pokfulam Rd, Hong Kong, SAR, China; e-mail: dcllam@hku.hk

Financial/nonfinancial disclosures: The author has reported to CHEST that no potential conflicts of interest exist with any companies/organizations whose products or services may be discussed in this article.

Reproduction of this article is prohibited without written permission from the American College of Chest Physicians. See online for more details.

Chest. 2013; 143(3):600-602. doi:10.1378/chest.12-2548

Text Size: A A A

Published online

Article

References

Extract

The square one question is why we need to do the epidermal growth factor receptor (EGFR) mutation tests. The answer is that there is corresponding targeted therapy, namely EGFR-tyrosine kinase inhibitor (TKI), for subjects with tumors that bear EGFR mutations at exons 18 to 21. This is in line with the strategy of personalizing therapy for lung cancer with the ultimate goals of making biomarker-based therapeutic decisions to receive EGFR-TKI and to improve treatment outcome in patients with advanced-stage non-small cell lung cancer (NSCLC).¹

First Page Preview

View Large

Sign In to Access Full Content

Username

Password

Forgot Your Password?

Want to Purchase a Subscription?

New to CHEST? Become an ACCP member to receive a full subscription to both the print and online editions.

Access Options:

Want to access your Institution's subscription?

Sign in to your individual user account while you are actively authenticated on this website via your institution (Learn more about institutional authentication). We will then sustain your personal access to their content/subscription for 90 days, after which you can repeat this process.

Sign In to Access Full Content

Username

Password

Forgot Your Password?

Want to Purchase a Subscription?

New to CHEST? Become an ACCP member to receive a full subscription to both the print and online editions.

Access Options:

Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s “Cited By” API will populate this tab (http://www.crossref.org/citedby.html).

Compression-Only CPR: Pushing the Science Forward
Cone
AAM 2010;304:1493-1495.

All you need to read in the other general jounals
BMJ 2010;341:c5893-c1494.

Some tools below are only available to our subscribers or users with an online account.

Print
PDF
Email

CHEST

Recipient(s) will receive an email with a link to
Counterpoint: Should Epidermal Growth Factor Receptor Mutations Be Routinely Tested for in Patients With Lung Cancer? No

Your Name:*
Example: John Doe

Email Address:* CC Me:
Enter your valid email address. Example: jdoe@example.com

Recipient's Email Address:*

Separate multiple email address with semi-colons (up to 5).

Subject:*
Subject for your email.

Message:
(Optional, message will truncate at 1000 characters)

Submit Cancel

Copyright in the material you requested is held by the American College of Chest Physicians (unless otherwise noted). This email ability is provided as a courtesy, and by using it you agree that that you are requesting the material solely for personal, non-commercial use, and that it is subject to the American College of Chest Physicians’ Terms of Use. The information provided in order to email this topic will not be used to send unsolicited email, nor will it be furnished to third parties. Please refer to the American College of Chest Physicians’ Privacy Policy for further information.

Copyright © American College of Chest Physicians. All rights reserved.
Share
Get Citation

Counterpoint: should epidermal growth factor receptor mutations be routinely tested for in patients with lung cancer? no
Lam DL.
Chest
.
2013;143(3):600-602.
doi:10.1378/chest.12-2548.

Download citation file:

RIS (Zotero)

EndNote

BibTex

Medlars

ProCite

RefWorks

Reference Manager

Copyright © American College of Chest Physicians
Get Permissions
Article Alerts

Processing your request... Please Wait.